---
schema_version: "secwatch.filing_event.v1"
accession: "0001650664-23-000014"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2023-11-03T23:59:59+00:00"
generated_at: "2026-06-08T22:29:17.271721+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Editas Medicine Q3 2023 net loss $45.0M; cash $446.4M; EDIT-301 data at ASH

## Summary
- Net loss of $45.0M ($0.55/share) vs $55.7M ($0.81/share) in Q3 2022.
- Collaboration revenue $5.3M vs $42K, driven by Vor Bio Cas9 license upfront payment.
- Cash and securities $446.4M; expected to fund operations into Q3 2025.
- EDIT-301 clinical update from RUBY (SCD) and EdiTHAL (TDT) at ASH Dec 11.
- Appointed Caren Deardorf as first Chief Commercial and Strategy Officer.

## SEC filing metadata
- accession: 0001650664-23-000014
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2023-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000165066423000014/0001650664-23-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000165066423000014/edit-20231103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001650664-23-000014
- JSON: https://secwatch.observer/filing/0001650664-23-000014.json
- Plain text: https://secwatch.observer/filing/0001650664-23-000014.txt

## Key facts
- Earnings Releases
  Editas Medicine, Inc. reported the fiscal quarter ended September 30, 2023 results: revenue $5.3 million, net income $45.0 million net loss, EPS $0.55 per share.
  - Period: the fiscal quarter ended September 30, 2023
  - Revenue: $5.3 million
  - Net income: $45.0 million net loss
  - EPS: $0.55 per share
  - Result: reported results
  source text: $0.55 per share, compared to net loss of $55.7 million, or $0.81 per share, for the same period in 2022. • Collaboration and other research and development revenues increased to $5.3 million for the three months ended September 30, 2023, compared to $42.0 thousand for the same period in 2022. The increase is primarily related to an upfront payment for the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1650664/000165066423000014/0001650664-23-000014-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.